Melatonin Replacement for Treatment of Sleep Disruption
The purpose of this study is to determine if replacing melatonin function with a melatonin agonist (ramelteon) in individuals that lack endogenous melatonin production (tetraplegia) helps to alleviate self-reported sleep disruption.
Stanford is not currently accepting new patients for this trial. You may want to check clinicaltrials.gov to see if other locations are recruiting.
- drug : Placebo
- drug : ramelteon
Phase: Phase 4
Ages Eligible For Study:
- Age 18 years or older, male or female veterans of any racial or ethnic group - Neurologically complete (Frankel A or B) damage to the lower (C4-C8) cervical spinal cord - Absence of melatonin production - Time since SCI is greater than 6 months [no cases of acute spinal cord injury] - Subjective complaint of sleep disruption